Company profile: TG Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for hematologic malignancies and autoimmune disorders, including BRIUMVI, a treatment for relapsing forms of multiple sclerosis—clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease—in adults.
Products and services
- Autoimmune Therapeutic Agents Development: Develops biopharmaceutical-grade therapeutic agents for treatment of autoimmune disorders, creating products intended for immune-mediated disease intervention consistent with TG Therapeutics’ mission
- BRIUMVI: Adult-indicated therapy for relapsing forms of multiple sclerosis
- Treats clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults with relapsing MS
- Hematologic Malignancy Therapeutic Agents Development: Engineers biopharmaceutical-grade therapeutic agents for treatment of hematologic malignancies, building products intended for oncology applications in hematology indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TG Therapeutics
Cidara Therapeutics
HQ: United States
Website
- Description: Provider of drug-Fc conjugate therapeutics built on the Cloudbreak platform, which couples targeted small molecules and peptides to a human antibody fragment (Fc) to inhibit disease targets and engage the immune system; includes CD388, a Phase 2 DFC for preventing seasonal influenza A and B, and CBO421, an IND-enabling oncology DFC targeting CD73 to enhance anti-tumor immunity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cidara Therapeutics company profile →
Curevo Vaccine
HQ: United States
Website
- Description: Provider of next-generation, non-mRNA vaccines for infectious diseases, developing Amezosvatein for the prevention of shingles and chickenpox.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curevo Vaccine company profile →
Alentis Therapeutics
HQ: Switzerland
Website
- Description: Provider of CLDN1-targeted therapeutics for CLDN1+ cancers and fibrosis. This clinical-stage Swiss-French biotech develops anti-CLDN1 antibodies and ADCs, including ALE.C04 (mAb for CLDN1+ tumors that opens the collagen barrier), Lixudebart (mAb to reverse liver, kidney, and lung fibrosis), and preclinical ADCs ALE.P02 (delivers a tubulin inhibitor) and ALE.P03 (delivers a topoisomerase I inhibitor) into tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alentis Therapeutics company profile →
Anocca
HQ: Sweden
Website
- Description: Provider of biotechnology, immunology, and immunotherapeutic drug discovery and development services focused on T-cell biology, offering engineered TCR-T cell therapies and the Anocca OS platform for modeling, analysis, visualization, and automation, with a TCR-T oncology pipeline targeting diverse cancers and future programs for infectious diseases, autoimmunity, and allergies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anocca company profile →
Achilles Therapeutics
HQ: United Kingdom
Website
- Description: Provider of patient-specific cancer immunotherapies that harness the immune system to target truncal tumor neoantigens. Offers PELEUS, an AI-powered bioinformatics platform to identify clonal neoantigens; VELOS, a manufacturing process to create clonal neoantigen-reactive T cell (cNeT) products; and cNeT cell therapies targeting multiple clonal neoantigens to treat cancer while sparing healthy tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achilles Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TG Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TG Therapeutics
2.2 - Growth funds investing in similar companies to TG Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TG Therapeutics
4.2 - Public trading comparable groups for TG Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →